MageA1-TCR gene therapy - MediGene

Drug Profile

MageA1-TCR gene therapy - MediGene

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediGene AG
  • Class Immunotherapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 06 Sep 2017 Medigene AG files CTA applicationin Germany for Multiple myeloma
  • 06 Sep 2017 MediGene plans a phase I/II trial for Multiple myeloma in Germany in December 2017
  • 17 Mar 2017 MediGene plans a phase I/II trial for an undisclosed indication in the second half of 2018 (MediGene pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top